12 completed, 2 withdrawn, 1 unknown. 15 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Completed 12, Withdrawn 2, Unknown 1 |
| Phase 3 | 2 | Unknown 1, Withdrawn 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow pramlintide: new trials by email Literature Review of pramlintide trials Research Report on pramlintide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tailoring Obesity Treatment Trial Pramlintide Acetate 1 MG/ML, Semaglutide Pen Injector, Sodium Chloride 0.9% Inj - Obesity, Appetite Regulation | Phase 2 / Phase 3 | Withdrawn | Esbjerg Hospital - University Hospital of Southern Denmark | 2025-04-01 | 2026-04-17 | |
| A Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 Diabetes Pramlintide, Lyumjev, Automated Insulin Delivery (AID) system - type1diabetes, Diabetes Mellitus, Type 1 | Phase 2 / Phase 3 | Unknown | McGill University Health Centre/Research Institute of the McGill University Health Centre | 30 | 2023-11-30 | 2024-04-18 |
| Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D PRAM9, Regular Insulin + Pramlintide, Regular Insulin - Diabetes Mellitus, Type 1, Insulin-dependent Diabetes Mellitus | Phase 2 | Completed | Xeris Pharmaceuticals | 18 | 2019-08-22 | 2024-03-27 |
| Effectiveness Study of Pramlintide to Treat Post-Transplant Diabetes Mellitus Pramlintide - Diabetes Mellitus | Phase 1 / Phase 2 | Withdrawn | University of Colorado, Denver | 2009-08-01 | 2018-07-26 | |
| Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin Placebo, Pramlintide and Metreleptin - Obesity | Phase 2 | Completed | AstraZeneca | 274 | 2008-11-01 | 2015-04-15 |
| Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects pramlintide acetate, metreleptin, placebo-P - Overweight, Obesity | Phase 2 | Completed | AstraZeneca | 636 | 2008-04-01 | 2015-04-15 |
| A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects pramlintide acetate, sibutramine, phentermine - Overweight, Obesity | Phase 2 | Completed | AstraZeneca | 258 | 2006-11-01 | 2015-03-06 |
| A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects pramlintide acetate 360 mcg, metreleptin, placebo-pramlintide 600 uL - Overweight, Obesity | Phase 2 | Completed | AstraZeneca | 177 | 2006-10-01 | 2015-04-14 |
| A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus pramlintide acetate - Type 1 Diabetes Mellitus | Phase 2 | Completed | AstraZeneca | 12 | 2006-04-01 | 2015-03-06 |
| A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects pramlintide acetate, placebo - Obesity | Phase 2 | Completed | AstraZeneca | 210 | 2005-09-01 | 2015-06-11 |
| A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects pramlintide acetate - Obesity | Phase 2 | Completed | AstraZeneca | 400 | 2005-05-01 | 2015-04-10 |
| Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects pramlintide acetate - Overweight, Obesity | Phase 2 | Completed | AstraZeneca | 184 | 2004-08-01 | 2015-06-11 |
| Evaluation of an Orally Administered Medication When Taken in Conjunction With Pramlintide Pramlintide acetate - Diabetes Mellitus, Non-Insulin-Dependent | Phase 2 | Completed | AstraZeneca | 24 | 2002-08-01 | 2015-05-21 |
| Evaluation of the Effect of Pramlintide on Satiety and Food Intake Pramlintide acetate, Placebo - Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | Phase 2 | Completed | AstraZeneca | 51 | 2002-07-01 | 2015-10-21 |
| Evaluation of the Bioavailability of Pramlintide Pramlintide acetate - Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | Phase 2 | Completed | AstraZeneca | 75 | 2002-06-01 | 2015-09-23 |
Obesity (8) · Diabetes Mellitus, Type 1 (5) · Overweight (4) · Diabetes Mellitus, Type 2 (3) · Weight Loss (2) · Diabetes Mellitus (1) · Insulin Resistance (1) · Prediabetic State (1)
AstraZeneca (11) · Esbjerg Hospital - University Hospital of Southern Denmark (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · University of Colorado, Denver (1) · Xeris Pharmaceuticals (1)
United States (12) · Australia (1) · Canada (1) · Denmark (1)
Lisa Porter, MD (6) · Ahmad Haidar, Ph.D. (1) · Andrea Valasquez (1) · Boris Draznin, M.D., Ph.D. (1) · Claus Bogh Juhl, MD, phd, professor (1) · George Atiee (1) · Jean Chan, MD (1) · Laurent Legault, M.D. (1) · Melissa-Rosina Pasqua, M.D. (1) · Michael Tsoukas, M.D. (1) · Michael Vallis, Ph.D. (1) · Natasha Garfield, M.D. (1)